Vectura Group plc Notice of Results (4580O)
09 February 2021 - 9:34PM
UK Regulatory
TIDMVEC
RNS Number : 4580O
Vectura Group plc
09 February 2021
Notice of Preliminary Results
Chippenham, UK - 9 February 2021 : Vectura Group plc (LSE: VEC)
("Vectura" or "the Group"), an industry-leading inhalation CDMO,
plans to announce its Preliminary Results for the year ended 31
December 2020 on Tuesday 9 March 2021.
Will Downie, Chief Executive Officer, and Paul Fry, Chief
Financial Officer will host a live webcast and conference call for
analysts at 9:30am GMT on the morning of the results.
Access to the webcast and presentation slides will be made
available on Vectura's website .
- Ends-
For more information, please contact:
Vectura Group plc
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / David Daley
About Vectura
Vectura is a provider of innovative inhaled drug delivery
solutions that enable partners to bring their medicines to
patients. With differentiated proprietary technology and
pharmaceutical development expertise, Vectura is one of the few
companies globally with the device, formulation and development
capabilities to deliver a broad range of complex inhaled
therapies.
Vectura has thirteen key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFLFVIFFIAIIL
(END) Dow Jones Newswires
February 09, 2021 05:34 ET (10:34 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024